sipatrigine has been researched along with flunarizine in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Anger, T; Madge, DJ; Mulla, M; Riddall, D | 1 |
| Bennis, K; Ducki, S; Lesage, F; Vivier, D | 1 |
| Cho, YS; Hwang, EM; Jung, SY; Lim, SM; Min, SJ; Pae, AN; Park, KD; Viswanath, AN | 1 |
2 review(s) available for sipatrigine and flunarizine
| Article | Year |
|---|---|
Medicinal chemistry of neuronal voltage-gated sodium channel blockers.
Topics: Amyotrophic Lateral Sclerosis; Analgesics; Anticonvulsants; Epilepsy; Humans; Ion Channel Gating; Models, Molecular; Mutation; Nerve Tissue Proteins; Neuroprotective Agents; Protein Binding; Sodium Channel Blockers; Sodium Channels; Stroke | 2001 |
Perspectives on the Two-Pore Domain Potassium Channel TREK-1 (TWIK-Related K(+) Channel 1). A Novel Therapeutic Target?
Topics: Arrhythmias, Cardiac; Depression; Epilepsy; Humans; Inflammation; Models, Molecular; Molecular Structure; Neuroprotective Agents; Pain; Potassium Channels, Tandem Pore Domain; Structure-Activity Relationship | 2016 |
1 other study(ies) available for sipatrigine and flunarizine
| Article | Year |
|---|---|
Identification of the first in silico-designed TREK1 antagonists that block channel currents dose dependently.
Topics: Animals; Computer Simulation; Crystallography, X-Ray; Dose-Response Relationship, Drug; HEK293 Cells; Humans; Mice; Mice, Knockout; Molecular Docking Simulation; Potassium Channels, Tandem Pore Domain | 2016 |